9 articles3,661 citations
Soft Tissue and Visceral Sarcomas: Esmo–euracan–genturis Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up
Gronchi, Stacchiotti·Annals of Oncology·2021·901 citations
Adjuvant Chemotherapy with Doxorubicin, Ifosfamide, and Lenograstim for Resected Soft-Tissue Sarcoma (EORTC 62931): A Multicentre Randomised Controlled Trial.Citation only
Woll, Hohenberger·Lancet Oncol·2012·597 citations
Bone Sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up.Citation only
Strauss, Stacchiotti·Ann Oncol·2021·492 citations
Prognostic Factors Influencing Progression-Free Survival Determined from a Series of Sporadic Desmoid Tumors: A Wait-And-See Policy According to Tumor Presentation.Citation only
Salas, Coindre·J Clin Oncol·2011·386 citations
Improved Survival Using Specialized Multidisciplinary Board in Sarcoma Patients.Citation only
Blay, Le Cesne·Ann Oncol·2017·384 citations
Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment.Citation only
Fiore, Bonvalot·Ann Surg Oncol·2009·376 citations
Denosumab in Patients with Giant-Cell Tumour of Bone: A Multicentre, Open-Label, Phase 2 Study.Citation only
Chawla, Palmerini·Lancet Oncol·2019·257 citations
Surgical versus Non-Surgical Approach in Primary Desmoid-Type Fibromatosis Patients: A Nationwide Prospective Cohort from the French Sarcoma GroupCitation only
Penel, Blay·Eur J Cancer·2017·188 citations
Vimseltinib versus Placebo for Tenosynovial Giant Cell Tumour (MOTION): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.Citation only
Gelderblom, Tap·Lancet·2024·80 citations